Aldesleukin (Recombinant interleukin-2). A review of its pharmacological properties, clinical efficacy and tolerability in patients with renal cell carcinoma (vol 7, pg 285, 1997)

被引：0
|
作者：
Jeal, W
Goa, KL
机构：
来源：
BIODRUGS | 1997年 / 8卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：192 / 192
页数：1
相关论文
共 50 条
  • [31] RETRACTION: Update on the Application of Interleukin-2 in the Treatment of Renal Cell Carcinoma (Retraction of Vol 13, Pg S 716, 2007)
    不详
    CLINICAL CANCER RESEARCH, 2018, 24 (15) : 3783 - 3783
  • [32] Efficacy of gabapentin on pruritus induced by interleukin-2 (IL-2) treatment in patients with metastatic renal cell carcinoma and melanoma
    Lee, S.
    Rusciano, V.
    Dutcher, J. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] T-cell subpopulation in patients with metastatic renal cell carcinoma treated by recombinant interleukin-2, recombinant interferon-α, 5-fluorouracil, and vinblastine
    Gez, E
    Mekori, T
    Struminger, L
    Rubinov, R
    Nativ, O
    Stein, A
    Haim, N
    Kuten, A
    CANCER INVESTIGATION, 1999, 17 (04) : 259 - 263
  • [34] SUBCUTANEOUS LOW-DOSE RECOMBINANT INTERLEUKIN-2 AND ALPHA-INTERFERON IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA
    RAVAUD, A
    NEGRIER, S
    CANY, L
    MERROUCHE, Y
    LEGUILLOU, M
    BLAY, JY
    CLAVEL, M
    GASTON, R
    OSKAM, R
    PHILIP, T
    BRITISH JOURNAL OF CANCER, 1994, 69 (06) : 1111 - 1114
  • [35] B7-H4 expression and its role in interleukin-2/interferon treatment of clear cell renal cell carcinoma
    Xu, Yipeng
    Zhu, Shaoxing
    Song, Mei
    Liu, Weihui
    Liu, Chengyi
    Li, Yongsheng
    Wang, Min
    ONCOLOGY LETTERS, 2014, 7 (05) : 1474 - 1478
  • [36] Phase I study of high-dose interleukin 2, aldesleukin, in combination with the histone deacetylase inhibitor, entinostat, in patients with metastatic renal cell carcinoma: Safety and tolerability results
    Pili, Roberto
    Shen, Li
    George, Saby
    Hammers, Hans J.
    Sandecki, Anita
    Collins, Connie
    Carducci, Michael Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [37] LACK OF EFFICACY OF LOW-DOSE SUBCUTANEOUS RECOMBINANT INTERLEUKIN-2 AND INTERFERON-ALPHA IN THE TREATMENT OF METASTATIC RENAL-CELL CARCINOMA
    THIOUNN, N
    MATHIOT, C
    DORVAL, T
    FLAM, TA
    TARTOUR, E
    MOSSERI, V
    ZERBIB, M
    FRIDMAN, WH
    DEBRE, B
    BRITISH JOURNAL OF UROLOGY, 1995, 75 (05): : 586 - 589
  • [38] POLYETHYLENE-GLYCOL CONJUGATED INTERLEUKIN-2 - CLINICAL AND IMMUNOLOGICAL EFFECTS IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA
    BUKOWSKI, RM
    YOUNG, J
    GOODMAN, G
    MEYERS, F
    ISSELL, BF
    SERGI, JS
    MCLAIN, D
    FYFE, G
    FINKE, J
    INVESTIGATIONAL NEW DRUGS, 1993, 11 (2-3) : 211 - 217
  • [39] Efficacy of gabapentin on pruritus induced by interleukin-2 (IL-2) treatment in patients with metastatic renal cell carcinoma and melanoma.
    Rusciano, Valerie
    Dutcher, Janice
    ONCOLOGY NURSING FORUM, 2007, 34 (02) : 535 - 536
  • [40] Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe
    Negrier, S
    Maral, J
    Drevon, M
    Vinke, J
    Escudier, B
    Philip, T
    CANCER JOURNAL FROM SCIENTIFIC AMERICAN, 2000, 6 : S93 - S98
12345